Modules
Modules
Genomics Primer
Genomics Primer
Overview/Key Objectives
What are Eukaryotic Cells?
DNA Definition
What are Chromosomes?
What is a Genome?
Regulation of Gene Expression in Eukaryotes
Genetic Alterations
References
Assessment Questions
Course Introduction
Course Introduction
Overview/Key Objectives
What is Precision Medicine?
Precision Medicine in the Clinic
Direct-to-Consumer Genomic Testing
Ongoing Genomic Research and Big Data in Precision Medicine
References
Assessment Questions
Pathology Assessment of Tumor Tissue
Pathology Assessment of Tumor Tissue
Overview/Key Objectives
Introduction to the Pathology Laboratory
Specimen Preparation
Initial Pathology Assessment
Common Pathology Tests Performed in Oncology
References
Assessment Questions
Introduction to Liquid Biopsies
Introduction to Liquid Biopsies
Overview/Key Objectives
What is a Liquid Biopsy?
Approaches to Liquid Biopsy Analysis: CTCs and cfDNA
Technologies for Isolation and Detection of CTCs and cfDNA
Liquid Biopsy Applications
Concordance Between Tumor and Liquid Biopsies for Mutational Analysis
Select Commercially Available Liquid Biopsy Assays
References
Assessment Questions
Lung Cancer: Assessment, Treatment
Lung Cancer: Assessment, Treatment
Introduction
Current Oncogenic Biomarkers in Lung Cancer
EGFR Epidermal Growth Factor
EGFR Exon 20 Insertions
EGFR Exon 18
ALK Anaplastic Lymphoma Kinase
ROS1 ROS Proto oncogene 1
BRAF v raf murine sarcoma viral oncogene homolog B
NTRK: Fusion Neurotrophic Tropomyosin Receptor Kinase
MET: Mesenchymal-to-Epithelial Transition
RET Fusion: Rearranged During Transfection
HER2: Human Epidermal Growth Factor 2
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
References
NTRK3 Fusion
NTRK3 Fusion
Initial Diagnosis
Clinical Progress and Treatment
Imaging
Pathology Part 1
Pathology Part 2
Discussion and Proposed Potential Therapies
References
Whole-Genome Sequencing
Whole-Genome Sequencing
Overview/Key Objectives
What is Whole-Genome Sequencing?
Sanger Sequencing
Whole-Genome Sequencing Methods
Whole-Genome vs. Whole-Exome Sequencing vs. Targeted Sequencing Panels
Strengths and Limitations of Next-Generation Sequencing
Next-Generation Sequencing in the Research and Clinic Settings
Importance of Bioinformatics
References
Assessment Questions
Genomic Medicine in Clinical Practice: Era of Personalized Medicine
Genomic Medicine in Clinical Practice: Era of Personalized Medicine
Overview/Key Objectives
Clinical Settings for Genomic Testing
Considerations When Choosing a Genomic Testing Approach
Liquid Biopsies
Frequently Discussed Topics
Future of Genomic Medicine
References
Assessment Questions
Quizzes
Tumor Boards
Videos
About
Visit Healio.com
Modules
Genomics Primer
Overview/Key Objectives
What are Eukaryotic Cells?
DNA Definition
What are Chromosomes?
What is a Genome?
Regulation of Gene Expression in Eukaryotes
Genetic Alterations
References
Assessment Questions
Course Introduction
Overview/Key Objectives
What is Precision Medicine?
Precision Medicine in the Clinic
Direct-to-Consumer Genomic Testing
Ongoing Genomic Research and Big Data in Precision Medicine
References
Assessment Questions
Pathology Assessment of Tumor Tissue
Overview/Key Objectives
Introduction to the Pathology Laboratory
Specimen Preparation
Initial Pathology Assessment
Common Pathology Tests Performed in Oncology
References
Assessment Questions
Introduction to Liquid Biopsies
Overview/Key Objectives
What is a Liquid Biopsy?
Approaches to Liquid Biopsy Analysis: CTCs and cfDNA
Technologies for Isolation and Detection of CTCs and cfDNA
Liquid Biopsy Applications
Concordance Between Tumor and Liquid Biopsies for Mutational Analysis
Select Commercially Available Liquid Biopsy Assays
References
Assessment Questions
Lung Cancer: Assessment, Treatment
Introduction
Current Oncogenic Biomarkers in Lung Cancer
EGFR Epidermal Growth Factor
EGFR Exon 20 Insertions
EGFR Exon 18
ALK Anaplastic Lymphoma Kinase
ROS1 ROS Proto oncogene 1
BRAF v raf murine sarcoma viral oncogene homolog B
NTRK: Fusion Neurotrophic Tropomyosin Receptor Kinase
MET: Mesenchymal-to-Epithelial Transition
RET Fusion: Rearranged During Transfection
HER2: Human Epidermal Growth Factor 2
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
References
Whole-Genome Sequencing
Overview/Key Objectives
What is Whole-Genome Sequencing?
Sanger Sequencing
Whole-Genome Sequencing Methods
Whole-Genome vs. Whole-Exome Sequencing vs. Targeted Sequencing Panels
Strengths and Limitations of Next-Generation Sequencing
Next-Generation Sequencing in the Research and Clinic Settings
Importance of Bioinformatics
References
Assessment Questions
Genomic Medicine in Clinical Practice: Era of Personalized Medicine
Overview/Key Objectives
Clinical Settings for Genomic Testing
Considerations When Choosing a Genomic Testing Approach
Liquid Biopsies
Frequently Discussed Topics
Future of Genomic Medicine
References
Assessment Questions
Quizzes
Tumor Boards
Videos
About
Login
Register
My Account
My Curriculum
Log Out
Visit Healio.com
Toggle navigation
Healio
Hematology/Oncology
Learn Genomics
Genomics Primer
Introduction to Liquid Biopsies
Module Content
Overview/Key Objectives
What is a Liquid Biopsy?
Approaches to Liquid Biopsy Analysis: CTCs and cfDNA
Technologies for Isolation and Detection of CTCs and cfDNA
Liquid Biopsy Applications
Concordance Between Tumor and Liquid Biopsies for Mutational Analysis
Select Commercially Available Liquid Biopsy Assays
References
Assessment Questions
Overview/Key Objectives
What is a Liquid Biopsy?
Approaches to Liquid Biopsy Analysis: CTCs and cfDNA
Technologies for Isolation and Detection of CTCs and cfDNA
Liquid Biopsy Applications
Concordance Between Tumor and Liquid Biopsies for Mutational Analysis
Select Commercially Available Liquid Biopsy Assays
References
Assessment Questions
0%
Your Module Progress
1.
Blood contains two types of cancer-derived materials, circulating tumor cells and cell-free circulating tumor DNA, both of which are susceptible to detailed molecular analysis.
Your Colleagues Responded
A. True
0%
B. False
0%
2.
For which of the following clinical applications can liquid biopsies be used?
Your Colleagues Responded
A. Screening for presence of disease
0%
B. Patient stratification and therapy selection
0%
C. Monitoring treatment response
0%
D. Detection of minimal residual disease after surgery or recurrence
0%
E. All of the above
0%
3.
One of the largest studies investigating cancer mutations in liquid biopsies demonstrated that liquid biopsies identified cancer mutations in 85% of all advanced tumors, and in nearly half of all cases, the biomarkers were associated with an approved targeted drug.
Your Colleagues Responded
A. True
0%
B. False
0%
4.
Studies have failed to demonstrate that liquid biopsies can detect resistant mutations, such as the T790M mutation found in patients with lung cancer who are progressing on
EGFR
inhibitor therapy.
Your Colleagues Responded
A. True
0%
B. False
0%
5.
Most studies have demonstrated high concordance rates (eg, > 80%) between tumor and liquid biopsy for detection of cancer mutations.
Your Colleagues Responded
A. True
0%
B. False
0%
6.
Which of the following is not a challenge or limitation to the use of liquid biopsies?
Your Colleagues Responded
A. May potentially miss biomarkers expressed in the tumor
0%
B. More costly than tumor biopsy and analysis
0%
C. Test variability
0%
D. Lack of consensus in technical approaches of choice
0%
7.
Which of the following statements is not true? Liquid biopsies:
Your Colleagues Responded
A. are a noninvasive method for identification of tumor markers, either as an alternative for patients whose tissue is unable to be biopsied or as an adjunct to evaluate drug response.
0%
B. provide an accurate snapshot of the genomic landscape of the tumor, bypassing issues such as intratumor heterogeneity
0%
C. facilitate tumor DNA sequencing because DNA crosslinking does not occur, compared with tissue biopsies in which DNA is often preserved in formalin-fixed paraffin-embedded blocks
0%
D. are the current gold standard for molecular analysis to identify actionable mutations in all patients
0%
8.
The cobas
EGFR
Mutation Test v2 (Roche) was the first liquid biopsy test approved by the FDA.
Your Colleagues Responded
A. True
0%
B. False
0%
Thank you for participating in this module. Click below to download the certificate.
Download Certificate of Participation
Previous Section
Continue
Next Module
×
Close
Notice